Global Tumor Tracking Systems Market By Based on Device Type (Direct Tumor Tracking Systems, Respiratory Tracking Systems), By Based on End-User (Ambulatory Surgical Centers , Other End-Users), By Application (Lung Cancer, Gastric Cancer, Breast Cancer, Others) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Tumor Tracking Systems Market Overview:

Tumor tracking systems are used to track a tumor in a patient’s body. It is crucial for radiation therapy to deliver a sufficient dose of radiation without damaging the surrounding healthy tissue. The localization of a tumor becomes difficult due to the patient’s shift in position, change of tumor area during a treatment series, and tumor movement due to respiration. Tumor Tracking Systems make imaging and radiotherapy more precise and safer for patients.

Detailed Segmentation:

The global tumor tracking systems market is segmented on the basis of device type, application, end-user, and region. A detailed segmental description is listed below:

Based on Device Type

• Direct Tumor Tracking Systems
• Respiratory Tracking Systems

Based on Application:

• Prostate Cancer
• Lung Cancer
• Gastric Cancer
• Breast Cancer
• Others

Based on End-User

• Hospitals & Clinics
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Other End-Users

Based on Region

• North America
  • The US
  • Canada
  • Mexico
• Europe
  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Korea
  • Rest of the Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East and Africa
  • GCC
  • Israel
  • South Africa
  • Rest of the MEA

Market Dynamics:

Drivers for the Global Tumor Tracking Systems Market

Cancer is one of the leading causes of death worldwide. This disease has significantly surged in prominence in recent decades and is expected to continue to grow in terms of prevalence over the forecast period. The use of technologically advanced devices such as Calypso, which provides real-time tumor monitoring with benefits such as not requiring ionizing radiation during tumor localization. These devices help surgeons to deliver treatment with minimal complications. Increased research & development activities to find the cure or improved treatment options for various cancers and to precisely locate a tumor, are expected to boost the revenue growth of the global tumor tracking systems market.

Opportunities for the Global Tumor Tracking Systems Market

The prevalence of prostate and breast cancer is a primary market growth driver. Increased investments by respective governments towards the use of biomarkers in drug discovery, specific tumor detection, and genetic studies for cancer identification is a significant element fueling market growth prospects. Additionally, a greater level of awareness and the availability of reimbursement policies are expected to create lucrative opportunities for this target market.

Restraints for the Global Tumor Tracking Systems Market

To provide tumor tracking systems, vast amounts of capital is required. Therefore, the need for high capital investments, as well as various technical issues related to sample collection and storage are major factors that could potentially restrain the market growth of the tumor tracking systems industry over the forecast period.

Competitive Landscape:

Key players in this market are –

• Cell Biolabs Inc.
• Genekam, Menarini Silicon Biosystems
• Miltenyi Biotec
• QIAGEN
• STEMCELL Technologies Inc.
• ThermoFisher Scientific
• Varian Medical Systems Inc. among others.

These key industry players are now focusing on mergers, partnerships, acquisitions, product developments, and collaboration strategies, in order to sustain their respective competitive edges.

Key Developments:

In March 2021, Varian announced an investment in Bend It Technologies Ltd., a medical device company.
In April 2021, Varian Medical Systems and Google Cloud entered into a collaboration to build an advanced artificial intelligence-based diagnostic platform to aid in the fight against cancer.
In May 2021, Qiagen announced to launch of a tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumors and precision medicine options in lung cancer.

For the Tumor Tracking Systems Market research study, the following years have been considered to estimate the market size: